Veracyte presents new Afirma Xpression Atlas data on MTC at ENDO
Veracyte announced that new data from the Afirma Xpression Atlas suggest that the majority of newly diagnosed medullary thyroid cancers, or MTC, are associated with variants from three genes. The findings shed new light on the genomic underpinning of this rare, but aggressive, form of thyroid cancer and were presented at ENDO, the Endocrine Society's annual meeting. For the study, researchers evaluated 77 preoperative fine needle aspiration biopsies from thyroid nodules that were positive for MTC based on Afirma testing and which spanned a range of Bethesda System cytology classification categories. All cases were subsequently evaluated with the Xpression Atlas, which uses RNA whole-transcriptome sequencing to detect 761 variants and 130 fusions in 511 genes that are associated with thyroid cancer. The scientists found that among the MTC cases, 55.8% harbored a RET variant, 9.1% included a KRAS variant, 7.8% contained an HRAS variant, while 2.6% of cases possessed fusions and 26% included no gene variants or fusions.